Bioclones Pioneering Success
Bioclones is a research, development
and production biotechnology company within the Sekunjalo Group, with its core business focused on the development and manufacture of quality, cost-effective and modern biotechnology products for human pharmaceutical use.

Click here to view the full article


Bioclones is a South African-owned biotechnology company dedicated to the manufacture of modern biotechnology products for human pharmaceutical use as well as the development of biotechnology infrastructure and skills across the African continent. It was established in 1982 and is the largest biotechnology company in this field in South Africa.

Bioclones has a track record of taking product from development to market. Work commencing in 1989 resulted in 1997 in the registration with the South African Medical Council of two formulations of recombinant human erythropoietin (r-HuEPO) in South Africa. Recombinant human erythropoietin is the worlds largest biotechnology product based on sales value (US$ 12.4 billion).

To date, Bioclones is the sole South African company that provides erythropoietin (REPOTIN®) to the South African state health department.

Bioclones has 22 worldwide patents which attract significant value. In addition to this, it has a product portfolio which when fully commercialized will compete in a global market that enjoys global revenue of US $ 12Billion.

Bioclones has made significant strides in the international scientific biotechnology community with three of its products being rated in the top ten by a prominent international publication.

Ribotech (Pty) Ltd, a Cape Town based subsidiary of Bioclones is making preparations to enter global biopharmaceutical markets through the manufacture of G-CSF.

Biopad, a biotechnology regional innovation centre established by the Department of Science and Technology, has invested US$ 5.3 m which will enable Ribotech (Pty) Ltd to develop G-CSF for world markets.

Bioclones has a strong pipeline of patent protected technologies focused principally on the enhancement of cellular immune response in humans for chronic viral diseases, such as HIV, HBV and HCV.

Copyright © 2008 l Bioclones